AR117206A1 - Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer - Google Patents

Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer

Info

Publication number
AR117206A1
AR117206A1 ARP190103484A ARP190103484A AR117206A1 AR 117206 A1 AR117206 A1 AR 117206A1 AR P190103484 A ARP190103484 A AR P190103484A AR P190103484 A ARP190103484 A AR P190103484A AR 117206 A1 AR117206 A1 AR 117206A1
Authority
AR
Argentina
Prior art keywords
formula
compound
group
independently selected
aryl
Prior art date
Application number
ARP190103484A
Other languages
English (en)
Original Assignee
Glaxosmithkline Ip Dev Ltd
Univ North Carolina Chapel Hill
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Univ North Carolina Chapel Hill, Viiv Healthcare Co filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR117206A1 publication Critical patent/AR117206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Compuestos derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido como miméticos de SMAC que activan la vía de ncNF-kB, una composición farmacéutica que los comprende y el uso de los mismos para el tratamiento de una infección por VIH y para la terapia del cáncer y de síndromes precancerosos. Reivindicación 1: Un compuesto representado por la fórmula (1), una sal farmacéuticamente del mismo o un estereoisómero del mismo, en el que: R, R’, R’’ y R’’’ se seleccionan independientemente entre H y CH₃; X¹ y X² se seleccionan independientemente entre el grupo que consiste en O y S; y L es un enlazador seleccionado entre el grupo que consiste en: (i) un compuesto de fórmula (2); (ii) un compuesto de fórmula (3); (iii) un compuesto de fórmula (4); (iv) un compuesto de fórmula (5); (v) un compuesto de fórmula (6); (vi) un compuesto de fórmula (7); (vii) un compuesto de fórmula (8); (viii) un compuesto de fórmula (9); (ix) un compuesto de fórmula (10); (x) un compuesto de fórmula (11); (xi) un compuesto de fórmula (12); y (xii) un compuesto de fórmula (13), en los que: Ar¹, Ar², Ar³, Ar⁴, Ar⁵, Ar⁶, Ar⁷, Ar⁸, Ar⁹, Ar¹⁰, Ar¹¹, Ar¹², Ar¹³, Ar¹⁴, Ar¹⁵, Ar¹⁶, Ar¹⁷, Ar¹⁸, Ar¹⁹, Ar²¹, Ar²², Ar²³, Ar²⁴, Ar²⁵ y Ar²⁶ se seleccionan cada uno independientemente de arilo C₆₋₁₄; Alk, Alk² y Alk³ se seleccionan cada uno independientemente entre: los compuestos de fórmula (14) y (15); R¹, es cicloalquilo C₃₋₆ o heterociclo C₁₋₆; R² se selecciona entre el grupo que consiste en -(CH₂)ₐ-, -(CH₂)ᵇ-O-(CH₂)ᶜ-, -(CH₂)ᵈ-aril C₆₋₁₄-(CH₂)ₑ- y -(CH₂)ᶠ-heteroaril C₁₋₆-(CH₂)ᵍ-; R³ se selecciona entre el grupo que consiste en -(CH₂)ₕ-; -(CH₂)ⁱ-O-(CH₂)ʲ-, -(CH₂)ₖ-aril C₆₋₁₄-(CH₂)ₗ- y -(CH₂)ₘ’-heteroaril C₁₋₆-(CH₂)ₘ’’-; R⁴ es cicloalquilo C₃₋₆, arilo C₆₋₁₄ o (CH₂)ₙ’-aril C₆₋₁₄-(CH₂)ₙ’’-, (CH₂)ₙ’’’-Alk-(CH₂)ₙ’’’’-, en donde n’, n’’, n’’’ y n’’’’ se seleccionan independientemente de 1 a 8; R⁵ es cicloalquilo C₃₋₆; R⁶ se selecciona del el grupo que consiste en (CH₂)ᶻ o un compuesto del grupo de fórmulas (16); a, b, c, d, e, f, g, h, i, j, k, I, m, m’, m’’, n, p, q, r, s, t, u, v, x, y y z se seleccionan cada uno independientemente de 1 a 12.
ARP190103484A 2018-11-30 2019-11-28 Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer AR117206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862773563P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
AR117206A1 true AR117206A1 (es) 2021-07-21

Family

ID=68808475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103484A AR117206A1 (es) 2018-11-30 2019-11-28 Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer

Country Status (15)

Country Link
EP (2) EP3886987B1 (es)
JP (2) JP7406556B2 (es)
KR (1) KR20210097154A (es)
CN (1) CN113613724A (es)
AR (1) AR117206A1 (es)
AU (1) AU2019390729B2 (es)
BR (1) BR112021010353A2 (es)
CA (1) CA3121140A1 (es)
CL (1) CL2021001388A1 (es)
ES (1) ES2968538T3 (es)
IL (2) IL283487B2 (es)
MX (2) MX2021006156A (es)
TW (2) TW202428584A (es)
WO (1) WO2020110056A1 (es)
ZA (1) ZA202103349B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
CN109475531B (zh) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
US10954243B2 (en) 2018-05-02 2021-03-23 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
PE20211050A1 (es) 2018-08-10 2021-06-04 Navire Pharma Inc Inhibidores de ptpn11
WO2020113213A2 (en) 2018-11-30 2020-06-04 Comet Therapeutics, Inc. Cyclic pantetheine derivatives and uses thereof
CA3160666A1 (en) * 2019-11-08 2021-05-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
US20240173276A1 (en) * 2021-03-23 2024-05-30 The University Of North Carolina At Chapel Hill Methods and compositions for inhibiting formation of the hiv latent reservoir

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
KR20030093248A (ko) 2001-03-19 2003-12-06 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
CA2651206C (en) 2006-05-05 2013-11-12 Shaomeng Wang Bivalent smac mimetics and the uses thereof
CN201013021Y (zh) 2006-11-24 2008-01-30 李一君 排水器改进结构
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2058312A1 (en) * 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8815927B2 (en) 2009-10-23 2014-08-26 The Regents Of The University Of Michigan Bivalent diazo bicyclic Smac mimetics and the uses thereof
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
US9546174B2 (en) * 2012-11-30 2017-01-17 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (IAP) antagonists
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
CA3160666A1 (en) * 2019-11-08 2021-05-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists

Also Published As

Publication number Publication date
JP2022509869A (ja) 2022-01-24
EP4342473A2 (en) 2024-03-27
CL2021001388A1 (es) 2021-11-05
IL283487A (en) 2021-07-29
EP3886987A1 (en) 2021-10-06
EP4342473A3 (en) 2024-05-15
CA3121140A1 (en) 2020-06-04
EP3886987B1 (en) 2023-11-15
WO2020110056A1 (en) 2020-06-04
TW202428584A (zh) 2024-07-16
AU2019390729B2 (en) 2022-08-11
AU2019390729A1 (en) 2021-06-03
JP7406556B2 (ja) 2023-12-27
ZA202103349B (en) 2022-12-21
CN113613724A (zh) 2021-11-05
IL283487B2 (en) 2024-07-01
TWI824069B (zh) 2023-12-01
MX2023014492A (es) 2024-01-25
EP3886987C0 (en) 2023-11-15
KR20210097154A (ko) 2021-08-06
JP2024023259A (ja) 2024-02-21
TW202039514A (zh) 2020-11-01
IL283487B1 (en) 2024-03-01
ES2968538T3 (es) 2024-05-10
IL310831A (en) 2024-04-01
BR112021010353A2 (pt) 2021-08-31
MX2021006156A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
AR117206A1 (es) Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
AR120700A1 (es) Inhibidores de kras g12c
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
BR112022012641A2 (pt) Compostos tricíclicos substituídos
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR102389A1 (es) Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095019A1 (es) Derivados de amatoxina
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
AR108906A1 (es) Heterociclos de biarilmetilo
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
CY1123955T1 (el) [8-(φαινυλοσουλφονυλο)-3,8-διαζαδικυκλο[3.2.1]οκτ-3-υλο](1η-1,2,3-τριαζολο-4-υλο)μεθανονες
AR103156A1 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos